BiotechTube

Secukinumab s.c. injection

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Autoimmunity, Inflammation

Conditions

Autoimmunity, Inflammation

Trial Timeline

Dec 22, 2020 → Apr 4, 2030

NCT ID
NCT04638647

About Secukinumab s.c. injection

Secukinumab s.c. injection is a approved stage product being developed by Novartis for Autoimmunity, Inflammation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04638647. Target conditions include Autoimmunity, Inflammation.

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04638647ApprovedRecruiting